Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 15 Life Science Startup Investors in Australia in April 2025

Last updated: Apr 2025 A list of 15 angel investors and VC (Venture Capital) funds that invest in Life science startups based in Australia. We rank investors based on the number of investments they made in Life science companies from Australia. We update this investor list every month.

Top 15 Life Science Startup Investors in Australia in April 2025

Investor	Life Science Australia investments
Main Sequence Ventures	2
The March Group	1
Catalio Capital Management	1
Accelerating Commercialisation - AusIndustry	1
Alium Capital	1
AbbVie Biotech Ventures	1
OneVentures	1
Possible Ventures	1
Bioplatforms Australia	1
Tin Alley Ventures	1
Benny Kleist	1
Skalata	1
Riverlane Capital	1
Medical Research Commercialisation Fund (MRCF)	1
Churchill Asset Management	1

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Series A, Series B
Australia, United States, Philippines

Portfolio highlights

Myriota — Myriota delivers cutting-edge IoT technology through low-cost, low-power satellite connectivity for global remote monitoring.
ElectraLith — ElectraLith develops direct lithium extraction and refining technology designed for efficient and sustainable lithium production.
Quantum Brilliance — Quantum Brilliance builds room temperature quantum computers powered by synthetic diamond, enabling applications in everyday computing, including edge and massively parrellelized computing.

A venture capital fund platform committed to supporting and investing in entrepreneurs and companies developing and bringing exponential technologies to food, health and sustainability. March's investment strategy involves becoming recognized as the leading investor in critical and transformative technology solutions, and aims to achieve thisby investing into companies and funds that focus on developing core intellectual property around game-changing sustainable solutions that are aligned with globally relevant sustainability trends and benefits.

Investment focus

SaaS, Energy, Retail
Seed, Series A, Series C
United States

Portfolio highlights

Digestiva — Digestiva develops the nutritional, sensory, and physiological properties of food and feed proteins with targeted biocatalysts.
EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.

Catalio Capital Management was created by George Petrocheilos and Dr. Jacob Vogelstein to invest in breakthrough biomedical technology companies created or referred by Catalio Capital Management, an elite group of world-renowned, serial scientist-entrepreneurs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Israel, Switzerland

Portfolio highlights

Perceive Pharma — Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.
Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
Aviceda Therapeutics — Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively.

A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda

Investment focus

Software, Mining, Hardware
Grant, Pre-Seed
Australia

Portfolio highlights

Neuromersiv — Neuromersiv empowers stroke and brain injury survivors with clinically designed virtual reality-based neurological rehabilitation solutions.
Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).

Alium Capital focuses on listed and unlisted technology investments to generate out-sized returns. The company invests in technology, innovation, and early-stage businesses, all the way through to publicly listed assets. It specializes in the fields of finance, investing, innovation, and capital.Alium Capital was founded in 2016 andheadquartered in Sydney, New South Wales.

Investment focus

Software, Financial Services, FinTech
Series A, Series B, Seed
Australia, United States, Singapore

Portfolio highlights

Beforepay — Beforepay understands that traditional pay cycles are a form of financial stress. So we set out to find a better way, giving Australians the control and confidence that comes with managing your own money, on your terms.That’s why we created Pay On Demand™ - a service that allows you to access the money you have earned at work, when you choose todo so. After all, it is yours!The app also automatically predicts when your bills are due, shows you how much is OK for you to spend, and automatically creates budgets for you, effortlessly.
Academy Xi — At Academy Xi, we help APAC's largest and most sophisticated organisations optimise performance with concise, actionable training solutions.
DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,274,002 freelance designers compete to create amazing designs for your business. Start Today!

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, Italy

Portfolio highlights

Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.

OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.

Investment focus

Software, Health Care, Biotechnology
Series A, Debt Financing, Funding Round
Australia, United States, Israel

Portfolio highlights

Hometime — At Hometime, we provide Airbnb property management solutions for homeowners and rental management business owners that help them scale and earn more.
StrongDM — Manage access to any server, database, or Kubernetes instance in minutes. Fully auditable, replayable, secure, and drag-and-drop easy.
Employment Hero — Employment Hero is Australia's top cloud-based HR, payroll and benefits platform for employers & employees. FREE trial for...

Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.

Investment focus

Software, Information Technology, Biotechnology
Seed, Pre-Seed, Series A
Germany, Australia, United States

Portfolio highlights

Heidi Health — Heidi Health is modernizing primary care with AI-powered technologies to improve care's quality and accessibility. its creators and engineers is to completely eradicate missed and sluggish diagnoses worldwide. They are committed to bridging the gap between the level of care that patients desire and the level of care that doctors can delivergiven their budget constraints. To create a platform where patients can quickly and easily get the treatment they require and to give every clinician the resources they need to deliver care that is secure, efficient,
HyperHeat — HyperHeat is a climate tech startup, that develops a breakthrough solution for zero-carbon industrial heat at very high temperatures.
Hippos Exoskeleton — Hippos Exoskeleton created an auto-inflating knee brace to avoid tears in the ACL and other injuries.

Bioplatforms Australia is a non-profit entity that supports life science research in genomic, proteomics, metabolomics, and bioinformatics.

Investment focus

AgTech, Farming, Agriculture
Pre-Seed
Australia

Portfolio highlights

Number 8 bio — Number 8 Bio is a scientist-led start-up in Sydney that makes scalable and affordable enteric methane mitigation feed additives for livestock. We have a unique approach to managing rumen energy flows and animal productivity when methane is decreased, and we aim to give farmers a healthy ROI when using the additives.

Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.

Investment focus

Medical, Health Care, Therapeutics
Pre-Seed
Australia

Portfolio highlights

Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
Remagine Labs — Remagine Labs is revolutionizing healthcare with a bluetooth-connected, wearable electro-pharmaceutical that provide patient-centered care and consistent drug administration, giving healthcare customers peace of mind all over the world.
Psychae Therapeutics — Neurala Biosciences is a biotechnology company creating transformative psychedelic-assisted therapies that combine the best of nature with modern pharmaceutical science. Our vision is to integrate the profound healing properties of botanical psychedelic substances with rigorous evidence-based medic

Benny Kleist is a Founder & COO of Eucalyptus.He attended The University of Queensland.

Investment focus

Education, E-Learning, Life Science
Pre-Seed, Series A
Australia, New Zealand

Portfolio highlights

Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
NextWork — Building the best online learning experience to switch careers and upskill. Join the waitlist today, we are waiting for you!

Giving Australian founders access to the education, capital and networks needed to build significant, sustainable, global businesses of the future.

Investment focus

Software, Information Technology, Marketplace
Pre-Seed, Seed
Australia, United States, United Kingdom

Portfolio highlights

TALY — TALY is a platform that is designed to find, manage and retain employees from both perfromance and personality for business development.
Viewa — Viewa is an augmented reality(AR) content publishing platform that brings print media such as magazines to life in 3D.
Enrola — Looking for online training courses? Discover the perfect course for you with our easy course advisor quiz. Get individual guidance and apply directly.

Long-term owner-operators of great Australian businesses.

Investment focus

Life Science, Biotechnology, Venture Capital
Series A
Australia

Portfolio highlights

Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.

Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.

Investment focus

Biotechnology, Health Care, Medical
Series A, Seed, Series B
Australia, United States, United Kingdom

Portfolio highlights

Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.

Churchill is a leading capital provider for private equity-owned, middle market companies. We provide first lien, unitranche, second lien and mezzanine debt, in addition to equity co-investments, secondary solutions and private equity fund commitments.

Investment focus

Health Care, Pet, Dental
Debt Financing, Private Equity
United States

Portfolio highlights

Proto Axiom — Early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Mosaic Dental Collective — Mosaic Dental Collective provides administrative and business operations support to dental practices. They are a multi-specialty group where doctors make decisions and are supported by an experienced professional management team.
Heartland Veterinary Partners — Heartland Veterinary Partners is high quality and fast growing veterinary support organizations.

Investors by industry